Bio News
Daewoong Pharmaceutical has acquired technology for a 3D liver organoid platform for toxicity assessment developed through a research project by the Ministry of Food and Drug Safety. Unlike conventional 2D cell models, the technology reproduces actual liver tissue and bile excretion structures, improving its ability to predict human responses. It can also maintain its function after long-term culture and freezing and thawing. The Ministry of Food and Drug Safety is pursuing international standardization of the technology under OECD test guidelines. If adopted, Daewoong Pharmaceutical is expected to manufacture and supply it.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
